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Adrenomedullary Secretion of Epinephrine Is 
Increased in Mild Essential Hypertension
Marie-Cécile Jacobs, Jacques W.M. Lenders, Jacques J. Willemsen, Theo Thien
Abstract To assess whether patients with mild essential hyper­
tension have excessive activities of the sympathoneuronal and 
adrenomedullary systems, we examined total body and forearm 
spillovers and norepinephrine and epinephrine clearances in 47 
subjects with mild essential hypertension (25 men, 22 women, 
aged 38.1 ±6,7 years) and 43 normotensive subjects (19 men, 24 
women, aged 36,5±5.9 years). The isotope dilution method with 
infusions of tritiated norepinephrine and epinephrine was used at 
rest and during sympathetic stimulation by lower body negative 
pressure at -15 and ~40 mmHg. Hypertensive subjects had a 
higher arterial plasma epinephrine concentration (0.20± 0.01 
nmol • L-1; mean ± SE) than normotensive subjects (0.15 ±0.01) 
(P<.01). The increased arterial plasma epinephrine levels ap­
peared to be due to a higher total body epinephrine spillover rate 
in the hypertensive subjects (0.23±0.02 nmol • min“1 • m-2) than 
the normotensive subjects (0.18±0.01) (P<.05) and not to a 
decreased plasma clearance of epinephrine. The arterial plasma
norepinephrine level, total body and forearm norepinephrine 
spillover rates, and plasma norepinephrine clearance were not 
altered in the hypertensive subjects. The responses of the cate­
cholamine kinetic variables to lower body negative pressure were 
not consistently different between normotensive and hypertensive 
individuals. These data indicate that individuals with mild essen­
tial hypertension (1) have elevated arterial plasma epinephrine 
concentrations that are due to an increased total body epineph­
rine spillover rate, indicating an increased adrenomedullary secre­
tion of epinephrine; (2) have no increased generalized sympatho­
neuronal activity and no increased forearm norepinephrine 
spillover; and (3) have similar responses of both the sympatho­
neuronal and adrenomedullary systems to sympathetic stimula­
tion by lower body negative pressure. (.Hypertension. 1997; 
29:1303-1308.)
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T he sympathetic nervous system not only plays an 
im portant role in the regulation of blood pres­
sure but is probably also involved in the patho­
genesis of human essential hypertension. Several lines of 
evidence indicate that hypertensive individuals have an 
elevated sympathetic neural outflow. Biochemical mea­
surements such as plasma catecholamine concentrations 
have been used extensively to document this. Several 
studies have reported on increased plasma NE or plasma 
EPI levels in hypertensive individuals, particularly in 
those younger than 40 years.1 However, plasma catechol­
amine concentrations are not a reliable index of sympa­
thoneuronal and adrenomedullary activities for several 
reasons. First, plasma N E and EPI levels are determined 
not only by the rate at which these catecholamines enter 
plasma but also by their rates of removal.2 Second, 
sympathetic outflow to different organs is not uniform, 
and in particular, during sympathetic stimulation, sym­
pathoneuronal responses show a differentiated pattern 
across different organs, depending on the kind of stim­
ulus.3 Thus, venous and even arterial plasma NE and 
EPI concentrations have a limited value as measures of 
sympathetic and adrenomedullary activities.
The isotope dilution m ethod can provide more de­
tailed information because there is a proportional rela-
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tionship between the sympathetic nerve firing rate to an 
organ and the spillover rate of norepinephrine into the 
circulation.4 This method enables calculation of spillover 
and clearance rates of N E and EPI, both for the whole 
body and for specific vascular beds. Several groups have 
investigated N E kinetics in hypertensive patients, show­
ing normal total body NE spillover with decreased 
neuronal uptake of NE or increased total body NE 
spillover in young hypertensive individuals.5-7 O ther 
investigators, however, have found no significant differ­
ence in total body spillover of NE between normotensive 
and hypertensive individuals.8
In contrast to NE kinetics, much less attention has been 
paid to EPI kinetics. Several studies have reported on 
increased plasma EPI levels in hypertensive individuals,1 
but it is unclear whether these increased plasma EPI 
concentrations are due to an increased adrenomedullary 
secretion of EPI or to a diminished clearance of EPI from 
plasma. So far, no direct comparison between normoten­
sive and hypertensive individuals has been carried out with 
regard to EPI kinetics.
The puipose of the present study was to assess simulta­
neously sympathoneuronal and adrenomedullary activities 
as measured by the isotope dilution technique, using simul­
taneous infusions of tritiated NE and tritiated EPI in 
untreated subjects with mild essential hypertension. Since 
excessive activity of the sympathoneuronal and adreno­
medullary systems may be disclosed only during sympa­
thetic stimulation, the kinetics of NE and EPI were also 
assessed during low and high intensities of LBNP.9,10
Methods
Subjects
Forty-seven subjects with mild essential hypertension and 43 
normotensive control subjects participated in the study. Before
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Selected Abbreviations and Acronyms
EPI = epinephrine 
FBF = forearm blood flow 
LBNP = lower body negative pressure 
NE = norepinephrine
entiy into the study, all participants (aged 20 to 45 years) had 
a negative medical history and a normal physical examination. 
Thirty-one of the 47 hypertensive subjects had discontinued 
their antihypertensive medication for at least 4 weeks before 
the study, and the remaining 16 had not yet received any 
anti hypertensive treatment. Blood pressure was measured at 
two occasions (in triplicate at each occasion after 10 minutes of 
supine rest) at 2-week intervals with a mercury sphygmoma­
nometer. Mild hypertension was defined as a diastolic pressure 
between 90 and 105 mm Hg 4 weeks after antihypertensive 
therapy had been stopped. Secondary hypertension was ex­
cluded according to standard clinical criteria. Normotension 
was defined as a blood pressure of less than 140/90 mm Hg. 
Subjects with a body weight higher than the ideal body weight 
plus 10% were excluded from the study.11 The normotensive 
control subjects were recruited by means of a newspaper 
announcement. The study protocol was approved by the Hos­
pital Ethics Committee, and all subjects gave their written 
informed consent.
Study Protocol and Procedures
AJÍ subjects were required to abstain from alcohol, nicotine, 
and caffe in ated foods and beverages for at least 24 hours before 
each study. The subjects were allowed to eat a light breakfast 2 
hours before the study. All experiments were carried out in the 
morning in a temperature-controlled room (21°C to 22°C). 
During the study, the subjects remained supine. The lower 
body of the subjects was sealed at the iliac crests in an airtight 
Plexiglas LBNP box. The applied subatmospheric pressure was 
recorded by a manometer connected to the inside of the box.
After local anesthesia, a brachial artery was cannulated 
(Angiocath, 20 gauge, Deseret Medical, Becton Dickinson) for 
monitoring blood pressure and heart rate (Hewlett-Packard 
GmbH) and for drawing arterial blood samples. An intrave­
nous cannula was inserted into a deep brachial vein in the 
ipsilateral arm for drawing venous blood samples. A venous 
cannula in the contralateral arm was used for simultaneous 
infusion of the radiotracers, FBF was recorded in the same arm 
that was also used for collection of arterial and venous blood 
samples, with the use of venous-occlusion strain-gauge pleth­
ysmography (Hokanson EC4, *DE Hokanson) with air-filled 
cuffs.12 During FBF measurement and blood sampling, the 
hand circulation was excluded by inflation of a wrist cuff to 
100 mm Hg above systolic pressure.13 After instrumentation, 
the subjects rested for 30 minutes. Thereafter, both radiotrac­
ers were infused, each as a bolus of 15 ¡jlCí * mf2, followed by a 
constant infusion at a continuous rate of 0.35 /xCi • min"1 • m-2 
for a total duration of 90 minutes. During the last 3 minutes of 
the 30-minute rest period, baseline recordings of intra-arterial 
blood pressure, heart rate, and FBF were obtained, and arterial 
and venous blood samples were drawn for measurement of 
labeled and unlabeled plasma catecholamines. Blood pressure 
was recorded simultaneously with the FBF measurement. FBF 
was measured three times per minute. Thereafter, LBNP was 
applied at an intensity of -15 mmHg for 15 minutes. Blood 
pressure, heart rate, and FBF recordings were made and blood 
samples collected in this sequence during the last 3 minutes of 
this LBNP period. After 30 minutes of rest, another LBNP 
period at -4 0  mm Hg for 15 minutes followed, with similar 
obtainment of blood pressure, heart rate, and FBF recordings 
and arterial and venous blood samples. The syringes containing 
the radiotracers were weighed before and after the infusion to
verify the infusion rate. Samples of the infusâtes were taken at 
the end of each infusion.
[3H]NE (levo-[ring-2,5,6-3H]-norepinephrine) (specific activ­
ity, 30 to 60 Ci/mmol) and [3H]EPI (levo-[N-methyl-3H]-epi- 
nephrine) (specific activity, 50 to 85 Ci/mmol) (DuPont~New 
England Nuclear) were sterilized with the use of a micropore 
filter (0,22 ¡xm) and diluted in 0.9% NaCl containing acetic (0.2 
mol/L) and ascorbic (5.7 mmol/L) acids. Sterilization, dilution, 
and storage took place under nitrogen. The vials were stored 
until use at — 80°C for a maximum of 3 months. Just before a 
study, an aliquot of each radiotracer was diluted in normal 
saline for intravenous infusion.
Analytic M ethods
Blood samples were collected into prechilled tubes contain­
ing 0.25 mol/L EGTA and 0.2 mol/L glutathione and immedi­
ately placed on melting ice. Plasma was separated by refriger­
ated centrifugation and frozen until assayed within 2 months 
from collection. The samples were analyzed for concentrations 
of unlabeled and tritiated NE and EPI using high-performance 
liquid chromatography with fiuorimetric detection after selec­
tive precolumn derivatization of the catecholamines with the 
fluorescent agent 1,2-diphenylethylenediamine.14
The detection limits of unlabeled NE and EPI are 2.2 and 3.2 
pmol/L, respectively. The intra-assay coefficients of variation of 
unlabeled NE and EPI at plasma levels of 1.31 and 0.11 nmol/L 
are 2.3% and 3.4%, respectively. At plasma levels of 1,02 and
0.15 nmol/L, interassay coefficients of variation are 8.5% and 
7.2%, respectively. The detection limit of [3H]NE and [3H]EPI 
is 6 disintegrations per minute. The interassay coefficient of 
variation of [3H]NE and [3H]EPI is 7.0% in venous plasma 
samples.
Data Analysis
Forearm vascular resistance was calculated as the quotient of 
mean arterial blood pressure and FBF and was expressed in 
arbitrary units (AU). The average of the hemodynamic data 
during the 3-minute recording was taken.
The total body clearance rate of each catecholamine was 
calculated from the infusion rate of each tritiated catecholamine 
([3H]CA) and the steady-state arterial plasma concentration of 
each tritiated catecholamine ([3H]CAarl) according to the formula 
Total Body CA Clearance (L * min-1 ■ m_2)=[3H]CA Infusion 
Rate (dpm ■ min’ 1 • m"2)/[3H]CAart (dpm • L~l). Total body spill­
over rate of each catecholamine was calculated from the arterial 
plasma catecholamine concentration (CAart) and the total body 
clearance of a catecholamine according to the formula Total Body 
CA Spillover (nmol * min-1 ■ n r 2)=CAart (nmol • L_1)xTotal 
Body CA Clearance (L • min"1 • m~2). The regional kinetic vari­
ables of each catecholamine in the forearm are expressed per 100 
mL forearm volume (FAV). Regional catecholamine spillover in 
the forearm was estimated from the following equation: Fore­
arm Spillover (pmol • 100 mL“* FAV ■ min“1):=[(CAven--CAart)+ 
(CAar(XFractional Extraction)] xFPF, where Fractional 
Extraction={[3H] CA;tn — [3H] CA^J/pH]CAar,} and FPF is fore­
arm plasma flow in milliliters per 100 mL forearm volume per 
minute, calculated from the FBF and hematocrit. The forearm 
clearance of each catecholamine was calculated according to the 
formula Forearm Clearance (mL-100 mL-1 FAV* min"l)= 
FPFxFractional Extraction of Each Catecholamine.
Data are expressed as mean±SE unless indicated otherwise. 
Differences between nomiotensive and hypertensive subjects were 
tested by the Mann-Whitney U test. For each variable, the 
responses to LBNP were tested by the Wilcoxon matched-pairs 
signed rank test. For calculation of correlations between 
hemodynamic and catecholamine kinetic variables, the Spearman 
correlation was used. A value of F<.05 was considered to be 
significant.
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T a b l e  1. Clinical Characteristics of Hypertensive and 
Normotensive Subjects
Characteristic Normotensive Hypertensive
n 43 47
Men/women 19/24 25/22
Age, y 36.5±5.9 38.1 ±6.7
Quetelet index, kg • r r r2 23.1 ±3.0 24.8±2.2t
Systolic pressure, mm Hg 119 ± 14 150±15
Diastolic pressure, mm Hg 73±9 98±8
Heart rate, bpm 67±10 72±11#
Urinary sodium, mmol/mmol 11.1 ±4.0 10.4±3.8
creatinine (n=37) (n-43)
Values are mean±SD.
*P<.05, tP<.01 vs normotensive subjects.
Results
B a se lin e  Values
The descriptive characteristics of all participants are 
summarized in Table 1. The ages of the normotensive and 
hypertensive groups did not differ significantly, but the 
hypertensive subjects had a slightly but significantly higher 
quetelet index than the normotensive subjects. As ex­
pected, blood pressure was higher in the hypertensive than 
normotensive subjects, as was heart rate. FBF was similar 
i n  the groups (1.65±0,12 and 1.51 ±0.10 mL - '100
m L " 1 • min“1, respectively), and forearm vascular resis­
tance  was slightly higher in the hypertensive (81 ±4 AU) 
th an  the normotensive (70±4 AU) subjects (P<,05).
Plasma NE concentrations did not differ significantly 
betw een  hypertensive and normotensive subjects (Table
2 ) . No differences were found in total body NE spillover 
a n d  clearance between hypertensive and normotensive 
subjects. Regional forearm NE spillover and clearance 
w e re  also similar in the two groups (Table 2, Fig 1). 
T h e re  was no correlation between systolic, diastolic, or 
m ean  arterial pressures and arterial plasma NE level or 
to ta l  body N E spillover.
Baseline arterial and venous plasma EPI concentrations 
w ere  significantly higher in the hypertensive (P c .01) than 
the  normotensive group (Table 2, Fig 2). Among all 
subjects, there were weak but significant correlations be­
tween arterial plasma EPI level and systolic pressure
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Fig 1. Individual values of NE spillover from the forearm in 
mildly essential hypertensive (HT) and normotensive control (NT) 
subjects. Triangles indicate male subjects; circles, female sub­
jects; and squares, mean±SE.
(r=.29; P<,01), diastolic pressure (r=.31; P<,01) 5 and 
heart rate (r=.25; P<.05). The total body spillover of EPI 
was significantly increased in the hypertensive subjects (Fig
3), whereas total body and forearm clearances of EPI were 
similar in both the hypertensive and normotensive groups. 
In both groups, there were extremely low forearm spill­
overs of EPI that were both significantly different from zero 
(P c .01), but there was no difference between values in 
normotensive and hypertensive subjects (Table 2).
Lower Body Negative Pressure
During LBNP at -1 5  m m Hg, both systolic and 
diastolic pressures did not change, but heart ra te  in­
creased slightly and significantly in both groups by + 1± 1 
and + 1±1  beats per minute. Pulse pressure decreased in 
the normotensive subjects by 2±1 m m H g (PC.Ol) and 
by 3±1 in the hypertensive subjects (PC.Ol), but these 
decrements were not significantly different. Forearm  
vascular resistance increased similarly in both groups by 
+  17±3 and +22±3 AU.
Venous and arterial plasma NE concentrations 
increased significantly by 31±3%  and 31±4%  in the 
normotensive subjects and by 34±5%  and 24±4%  in 
the hypertensive subjects (Table 2). The increments of
Table 2 . Baseline Values and Responses of Catecholamine Kinetic Variables to Lower Body 
Negative, Pressure at -1 5  mm Hg in Hypertensive and Normotensive Subjects
Kinetic Variable
Baseline Level Change at -1 5  mm Hg LBNP
Normotensive Hypertensive Normotensive Hypertensive
Norepinephrine
Venous plasma, nmol • L~1 1.13±0.09 1.29+0.09 0.34+0.05H 0.35±0,05||
Arterial plasma, nmol • L“1 0.83±0.05 0.95±0.05 0.23±0.03|( 0.18±0.03|l
Total body spillover, nmol • min"1 • n r 2 0.85±0.06 0.87±0.05 0.07±0.03 0.06±0.03t
Total body clearance, L • min-1 • m-2 1,03 ±0.03 0.95 ±0.03 —0.15±0.02j| —0.10±0.03§
Forearm spillover, pmol • 100 mL~1 • min-1 0.77±0.07 0.90±0.06 0.08±0.05 0.10+0.04$
Forearm clearance, mL • 100 mL~1 • min"1 0.64±0.04 0.69+0.04 -0.08±0.03|| -0.10±0.03§
Epinephrine
Venous plasma, nmol • L"1 0.04±0,01 0.06±0.01f 0.00±0.00 0.00±0.01
Arterial plasma, nmol • L_1 0.15±0.01 0.20±0.01f 0.06±0.01|| 0.06±0.01||
Total body spillover, nmol • min"1 • m- 2 0.18±0.01 0.23±0.02* 0.02±0.01* 0.03±0.01t
Total body clearance, L • m in'1 • m-2 1.22±0.04 1.14+0.04 -0.22+0.0311 — 0.16±0.03]|
Forearm spillover, pmol • 100 mL-1 ■ min"1 0.008±0.002 0.009+0.004 -0.001 ±0.002 0.000±0.006
Forearm clearance, mL * 100 mL"1 • min~1 0.69±0.04 0.74±0.05 -0 .0 7 ± 0 .0 4 t —0.12±0.03||
LBNP indicates lower body negative pressure. Values are mean±SE.
*P<.05, tP<-01 vs normotensive subjects; JPc.OS, §P<.001, ||P<.0001 vs baseline.
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Fig 2. Individual values of arterial plasma EPI concentration in 
mildly essentia! hypertensive (HT) and normotensive control (NT) 
subjects. Triangles Indicate male subjects; circles, female subjects; 
and squares, mean±SE *P<.01, hypertension vs normotension.
forearm  and to ta l body N E  spillovers reached signif­
icance only in the hypertensive group and not in the 
norm otensive group, bu t these increments were not 
significantly different be tw een  the groups (Table 2). 
Total body N E clearance decreased significantly in 
both groups.
Venous plasma E PI concentration did not change 
during LBNP at —15 mm Hg, but arterial plasma EPI 
level increased by 36± 5%  in the normotensive subjects 
and 38±7%  in the hypertensive subjects (P=NS) (Table
2). The increments in arterial plasma EPI levels during 
LBNP appeared to be due to both an increase in total 
body EPI spillover (normotensive subjects, +13 ±5%; 
hypertensive subjects, + 1 9 ± 6 % ) and a reduction in total 
body EPI clearance ( —17±2%  and -1 2 ± 3 % s respec­
tively), The forearm  spillovers of EPI did not increase 
significantly during LBNP in both groups (Table 2).
During LBNP at —40 mm Hg, pulse pressure de­
creased significantly m ore in the hypertensive group 
( —13 ±  1 mm Hg) than the normotensive group (—9±1) 
(j?<.05), whereas heart ra te  increased similarly in both 
groups by 1Q±1 and 9± 1  beats per minute, respectively 
(P ~ N S).
Venous plasma N E concentrations increased similarly by 
94±6%  and 111±11%  in the normotensive and hyperten­
c
I
«
o
Ec
>0
0.60-
0.40-
aW
-  0.20 a.
LU
>.
■Oo
-Q
w*->oH
0.00
r— 
• •
A
A
A A A
A •
A •  A
A •  •  •
*AA* A A *■
A
A •  •
A
A •
A •  
•  A
•  A •  •
A •  A* •
•  •  A
A A •• AA
•  A A 
A *  *
A A
A •  •  •  •
HT NT
Fig 3. Individual values of total body EPI spillover in mildly 
essential hypertensive (HT) and normotensive control (NT) sub­
jects. Triangles indicate male subjects; circles, female subjects; 
and squares, mean±SE. *P<.05, hypertension vs normotension.
sive subjects, respectively. Arterial NE increased more in 
the hypertensive (96±8% ) than the normotensive 
(83±8%) group (Table 3), whereas there was no difference 
between the groups with regard to the responses of fore­
arm and total NE spillovers as well as total body and 
forearm NE clearances (Table 3).
The responses of arterial plasma EPI concentrations 
increased by 108±10% in the normotensive subjects and 
136±18% in the hypertensive subjects (P=NS) (Table 3). 
The total body spillover of EPI increased by 69 ±12% and 
81 ±13%, whereas the total body clearance of EPI de­
creased by 16±6% and 21 ±3%. These differences between 
normotensive and hypertensive individuals were not signif­
icant. The forearm spillovers of EPI showed a slight but 
significant decrease in both groups.
Discussion
The present study not only confirms the previously 
reported elevated plasma EPI levels in individuals with 
essential hypertension but also demonstrates that this is 
due to an increased adrenomedullary release of EPI into 
the bloodstream and not to a decreased clearance of EPI. 
This is indicated by the increased total body spillover 
of EPI in combination with an unaltered EPI clearance.
*
Table 3. Baseline Values and Responses of Catecholamine Kinetic Variables to Lower Body 
Negative Pressure at -4 0  mm Hg in Hypertensive and Normotensive Subjects
Kinetic Variable
*
Baseline Levels Change at -4 0  mm Hg LBNP
Normotensive Hypertensive Normotensive Hypertensive
Norepinephrine
Venous plasma, nmol * L~1 1.17+0.10 1.26±0.09 1.02±0.10§ 1.18±0.09§
Arterial plasma, nmol • L~1 0.86±0,05 0.94+0.05 0.64±0.06§ 0.83±0.06*§
Total body spillover, nmol • min'1 • m"2 0.83±0.06 0.86±0.05 0.30+0.04§ 0.46±0.06§
Total body clearance, L • min’ 1 ■ m-2 0.96±0.03 0.92±0.03 -0.15+0.02§ -0.17+0.02§
Forearm spillover, pmol • 100 mL“1• min"1 0.82±0.08 0.82±0.08 0.36±0.11§ 0.36+0.07§
Forearm clearance, mL • 100 mL"1• min“1 0.64±0.04 0.62±0.04 -0.17±0.04§ -0 .14±0.05§
Epinephrine
Venous plasma, nmol • L“1 0.04±0.01 0.06+0.01 f 0.02+0.01§ 0.06±0.01f§
Arterial plasma, nmol • L_1 0.19+0.01 0.25+0.02t 0.19±0.02§ 0.34±0.07§
Total body spillover, nmol * min"1 • m"2 0.21 ±0.02 0.27±0.02* 0.12±0.02§ 0.23±0.06§
Total body clearance, L * min"1 • m-2 1.09±0.04 1.06±0.04 -0.21 +0.03§ —0.24±0.03§
Forearm spillover, pmol * 100 mL-1 • min-1 0.005±0.001 —O.Q06±0.005 -0.005±0.0024: -0 .025±0 .019 i
Forearm clearance, mL * 100 mL-1 • min~1 0.71 ±0.04 0.69 ±0.05 —0.22+0.04§ —0.19+0.04§
LBNP indicates lower body negative pressure. Values are mean±SE.
*P < .05, fP<-01 vs normotensive subjects; $P<.05, §P<.0001 vs baseline.
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Several previous studies have demonstrated elevated 
plasma EPI levels in individuals with essential hyperten­
sion,1’15-18 suggesting increased adrenomedullary secretion 
of EPI in hypertensive individuals. Although EPI is re­
leased from the adrenal medulla directly into the blood­
stream, arterial plasma EPI levels cannot be used as an 
index of adrenomedullary EPI secretion because most of 
the circulating EPI is removed rapidly from the circula­
tion.19 To take into account the removal of EPI from the 
circulation, adrenomedullary EPI secretion can be assessed 
by the isotope dilution technique.20 This technique requires 
a high analytic sensitivity for measurement of low venous 
EPI concentrations and venous [3H]EPI activity.14 With 
this technique, the present study demonstrates for the first 
time that the elevated plasma EPI levels in essential 
hypertensive individuals are due to an increased adreno­
medullary secretion of EPI. Since the adrenal medulla 
serves as a sympathetic ganglion, the increased adrenal EPI 
release in the mildly hypertensive individuals reflects an 
increased sympathetic outflow selectively to the adrenal 
medulla in these individuals.
Increased sympathetic nervous system activity has been 
implicated as an important pathophysiological mechanism 
in essential hypertension for a long time.21 Increased 
activity of the sympathetic system may not only be manifest 
at different levels of the sympathoneuronal axis but has also 
been demonstrated as an increased local NE spillover in 
certain organs, such as the heart, kidneys, brain, and 
skeletal muscles.6-7 The present observation demonstrates 
that this increased sympathetic outflow extends also to the 
adrenal medulla. In contrast, global sympathoneuronal 
activity, estimated as total body NE spillover, was not 
elevated in the hypertensive subjects. Tlais is at variance 
with some but not all previous studies, demonstrating an 
increased total body N E spillover in hypertensive sub­
jects.5’6 It should be noted that reports on NE kinetics or 
microneurographic data in hypertensive subjects have 
mainly been based on male subjects.22 The present study 
included an approximately equal number of male and 
female subjects in both groups.
A particular additional finding in the present study is the 
forearm spillover of EPI in both normotensive and hyper­
tensive individuals. These spillover rates, although ex­
tremely low, are significantly different from zero. Under 
normal conditions, EPI is mainly synthesized in the adrenal 
medulla and certain brain nuclei. However, in individuals 
with heart failure;but also in healthy subjects during 
intensive aerobic exercise, EPI can be released from the 
heart. This released EPI is EPI that is predominantly 
derived from the circulation, from which it is taken up by 
sympathetic nerves.23 Apparently, forearm EPI can recycle 
because it can be coreleased along with NE from sympa­
thetic nerves. EPI synthesis in the human forearm is 
unlikely, because the key enzyme (phenylethanolamine 
N-methyltransferase) necessary for the synthesis of EPI 
from NE has not been demonstrated in the forearm. 
Alternative possible explanations for the measured fore­
arm EPI spillover include an assay artifact, an isotope effect 
of [3H]EPI, or a delayed recycling of the [3H]EPI compared 
with unlabeled endogenous EPI because of a too short 
infusion time of the tracer.14 Thus, it is unclear whether the 
measured spillover of EPI in the forearm indicates a basal 
release of EPI. During sympathetic stimulation, as is the 
case during high-intensity LBNP, forearm EPI spillover did 
not increase but even decreased slightly. This could be
related to an increased forearm extraction of EPI because 
of the sympathetically induced decrease in FBF.
Sympathetic stimulation by low-intensity LBNP did not 
disclose any further differences in sympathoneuronal and 
adrenomedullary activities between normotensive and hy­
pertensive subjects. Low-intensity LBNP deactivates car­
diopulmonary baroreceptors,94” and with the use of the 
microneurographic technique, it has previously been shown 
that cardiopulmonary baroreceptor control of sympathetic 
nerve activity is enhanced in individuals with mild essential 
hypertension.24 In our study, however, the response of 
forearm NE spillover to cardiopulmonary baroreceptor 
deactivation in the hypertensive subjects was not enhanced. 
Although we did not measure muscle sympathetic nerve 
traffic by microneurography, it is unlikely that sympathetic 
nerve traffic response to LBNP was enhanced in the 
hypertensive subjects because the forearm vascular resis­
tance response in the hypertensive subjects was also not 
increased. The apparent discrepancy between the results 
obtained by microneurography and by NE kinetics might 
be explained by a different study population (borderline 
hypertensive versus mildly hypertensive individuals) or by 
an interfering effect of peripheral sympathoneuronal 
mechanisms such as neuronal reuptake of NE. In addition, 
it should be noted that we did not measure central venous 
pressure in this study. If the hypertensive subjects had had 
a smaller decrease in central venous pressure in response 
to low-intensity LBNP than the normotensive subjects, this 
might also have been an explanation for the similar incre­
ments in forearm NE spillover in the hypertensive 
individuals.
High-intensity LBNP deactivates both cardiopulmonary 
and arterial baroreceptor s.9,10 The arterial plasma levels of 
NE and EPI and total body spillovers of NE and EPI 
tended to increase more during high-intensity LBNP in the 
hypertensive than the normotensive group. This is probably 
caused by the larger fall in pulse pressure in the hyperten­
sive group during LBNP and therefore does not necessarily 
mean that the hypertensive subjects have an enhanced 
arterial baroreceptor control of sympathoneuronal and 
adrenomedullary activities. Previous studies have also 
shown a normal arterial baroreceptor control of sympa­
thetic activity in individuals with borderline hypertension.24 
In view of the larger decrease in pulse pressure in the 
hypertensive subjects, the apparent normal heart rate 
response to arterial baroreceptor deactivation in the hyper­
tensive subjects fits with the well-documented impaired 
arterial baroreceptor control of heart rate in mildly hyper­
tensive individuals.25
It is still unresolved whether an increased release of' 
adrenal EPI is of pathophysiological significance in essen­
tial hypertension. On the basis of evidence obtained in 
isolated tissue preparations and animal experiments,26-28 
Brown and Macquin29 hypothesized that intermittent in­
crements in circulating EPI facilitate the neuronal release 
of NE by a stimulating effect of EPI on the presynaptic 
j32-adrenergic receptors, thus contributing to the develop­
ment of hypertension. Support for this hypothesis came 
also from studies in humans showing that EPI has a 
facilitatory effect on peripheral noradrenergic transmission 
and that this effect was enhanced in individuals with 
essential hypertension.30*31 Individuals who develop hyper­
tension would be more susceptible to stressful stimuli and 
exhibit elevated stress-related increments in circulating 
EPI. Indeed, an abundance of evidence indicates that, in
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particular at a young age, individuals with essential hyper­
tension have increased sympathetic responses to psycho­
logical stress.15*32 The slightly increased plasma EPI con­
centrations in the hypertensive subjects fit with the 
hypothesis of Brown and Macquin.
A question of particular concern is whether the in­
creased plasma EPI levels may contribute to the delete­
rious cardiovascular sequelae of hypertension in the long 
term. The developm ent of these complications may be 
mediated by well-known adverse effects of catechol­
amines, such as induction of cardiac arrhythmias, stim­
ulation of vascular and ventricular hypertrophy, and 
activation of platelets.33*35 Although the arterial plasma 
EPI levels in the subjects with mild hypertension were 
only slightly higher than those in the normotensive 
subjects, it cannot be excluded that chronic exposure of 
the heart and blood vessels to this circulating EPI may 
be harmful in the long term.
In conclusion, this study demonstrates that individuals 
with mild essential hypertension have increased plasma 
EPI levels and that this is due to an increased basal 
adrenomedullary secretion of EPI. This indicates that 
mildly hypertensive subjects have an increased sympathetic 
outflow to the adrenals. In contrast to some previous 
studies, we did not find an increased general sympathoneu­
ronal activity, measured as total body NE spillover. No 
gross abnormalities were noted during sympathetic stimu­
lation by different levels of LBNP. It is tempting to 
speculate that the increased plasma EPI levels in the 
hypertensive subjects may be of pathophysiological signif­
icance for the development of the cardiovascular compli­
cations of hypertension in the long term.
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